IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition marked by the accumulation of IgG4-positive plasma ...

Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung ...

adding to Amgen Inc. (NASDAQ:AMGN)’s strong rare illness portfolio. With the introduction of new indications for UPLIZNA, a treatment for neuromyelitis optica spectrum disorder (NMOSD), the ...

2025 Healthcare & Pharmaceuticalscategory US FDA approves Amgen's Uplizna as first treatment for rare immune disorder April 3, 2025 Healthcare & Pharmaceuticalscategory US FDA declines to approve ...

It has some rivals in its push to the IgG4-RD market, notably Amgen which reported positive topline results from a phase 3 trial of its CD19-directed antibody Uplizna (inebilizumab), acquired as ...